Literature DB >> 18400557

Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats.

Mayu Nishio1, Yasushi Sakata, Toshiaki Mano, Tomohito Ohtani, Yasuharu Takeda, Takeshi Miwa, Masatsugu Hori, Tohru Masuyama, Takashi Kondo, Kazuhiro Yamamoto.   

Abstract

BACKGROUND: beta-blocker therapy is an established therapeutic strategy for systolic heart failure. However, its benefits in diastolic heart failure (DHF) are controversial. AIMS: This study was designed to investigate the effects of bisoprolol on DHF. METHODS AND
RESULTS: Dahl salt-sensitive rats fed on 8% NaCl diet from age 6 weeks, DHF model rats, were divided into three groups at age 13 weeks. One group was treated with bisoprolol 12.5 mg/kg/day (Low dose group, n=18), one group was treated with bisoprolol 250 mg/kg/day (High dose group, n=18), and there was also an untreated group (Untreated group, n=18). The survival rate was best in the High dose group. Left ventricular hypertrophy and the expression of proinflammatory cytokines in the myocardium were significantly attenuated in the High dose group, but not in the Low dose group, and oxidative stress was most suppressed in the High dose group. Measurement with electron spin resonance revealed that bisoprolol had a potent scavenging ability, and bisoprolol attenuated the down-regulation of peroxisome proliferation-activated receptor coactivator-1alpha, an important element in the mitochondrial reactive oxygen species detoxification system.
CONCLUSION: beta-blocker administration, particularly at high dose, improved the survival rate of the DHF model, at least partly through the attenuation of inflammatory changes and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400557     DOI: 10.1016/j.ejheart.2008.03.002

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  10 in total

Review 1.  Inflammation and therapy for hypertension.

Authors:  Cheryl L Laffer; Fernando Elijovich
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 2.  Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction.

Authors:  Kazuhiro Yamamoto
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

3.  Glucocorticoids Induce Cardiac Fibrosis via Mineralocorticoid Receptor in Oxidative Stress: Contribution of Elongation Factor Eleven-Nineteen Lysine-Rich Leukemia (ELL).

Authors:  Yosuke Omori; Toshiaki Mano; Tomohito Ohtani; Yasushi Sakata; Yasuharu Takeda; Shunsuke Tamaki; Yasumasa Tsukamoto; Takeshi Miwa; Kazuhiro Yamamoto; Issei Komuro
Journal:  Yonago Acta Med       Date:  2014-10-15       Impact factor: 1.641

4.  Bisoprolol reversed small conductance calcium-activated potassium channel (SK) remodeling in a volume-overload rat model.

Authors:  Yajuan Ni; Tingzhong Wang; Xiaozhen Zhuo; Bingxue Song; Jing Zhang; Feng Wei; Hongyuan Bai; Xuehui Wang; Dandan Yang; Li Gao; Aiqun Ma
Journal:  Mol Cell Biochem       Date:  2013-08-24       Impact factor: 3.396

5.  Distinct features of calcium handling and β-adrenergic sensitivity in heart failure with preserved versus reduced ejection fraction.

Authors:  Peter J Kilfoil; Sabine Lotteau; Rui Zhang; Xin Yue; Stephan Aynaszyan; Ryan E Solymani; Eugenio Cingolani; Eduardo Marbán; Joshua I Goldhaber
Journal:  J Physiol       Date:  2020-09-09       Impact factor: 5.182

Review 6.  The Efficacy of Various Pharmacological Agents on Long-Term Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Randomized Control Trials.

Authors:  Sana Faisal; Zubair Ahmad Ganaie; Saima Batool; Dr Hatim I Lokhandwala; Joseph Hankins; Sandipkumar S Chaudhari; Rimsha R Vohra; Shamsha Hirani
Journal:  Cureus       Date:  2022-08-18

7.  Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes.

Authors:  Dermot Phelan; Chris Watson; Ramon Martos; Patrick Collier; Anil Patle; Seamas Donnelly; Mark Ledwidge; John Baugh; Ken McDonald
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

8.  Gentisic acid attenuates pressure overload-induced cardiac hypertrophy and fibrosis in mice through inhibition of the ERK1/2 pathway.

Authors:  Simei Sun; Hae Jin Kee; Li Jin; Yuhee Ryu; Sin Young Choi; Gwi Ran Kim; Myung Ho Jeong
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

Review 9.  The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction.

Authors:  Xizhen Xu; Dao Wen Wang
Journal:  Int J Cardiol Heart Vasc       Date:  2019-12-13

10.  Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure.

Authors:  Milton Packer
Journal:  J Am Heart Assoc       Date:  2020-08-01       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.